Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardi… Read more
Eli Lilly and Company - Asset Resilience Ratio
Eli Lilly and Company (LLY) has an Asset Resilience Ratio of 8.63% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Eli Lilly and Company's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Eli Lilly and Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $9.79 Billion | 8.52% |
| Short-term Investments | $121.60 Million | 0.11% |
| Total Liquid Assets | $9.91 Billion | 8.63% |
Asset Resilience Insights
- Limited Liquidity: Eli Lilly and Company maintains only 8.63% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Eli Lilly and Company Industry Peers by Asset Resilience Ratio
Compare Eli Lilly and Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
PINK:NVSEF |
Drug Manufacturers - General | 0.13% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 7.18% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
Annual Asset Resilience Ratio for Eli Lilly and Company (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Eli Lilly and Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.35% | $3.42 Billion | $78.71 Billion | -0.23pp |
| 2023-12-31 | 4.57% | $2.93 Billion | $64.01 Billion | +0.10pp |
| 2022-12-31 | 4.47% | $2.21 Billion | $49.49 Billion | -3.54pp |
| 2021-12-31 | 8.01% | $3.91 Billion | $48.81 Billion | +0.11pp |
| 2020-12-31 | 7.89% | $3.68 Billion | $46.63 Billion | +1.69pp |
| 2019-12-31 | 6.21% | $2.44 Billion | $39.29 Billion | -10.67pp |
| 2018-12-31 | 16.87% | $7.41 Billion | $43.91 Billion | -0.99pp |
| 2017-12-31 | 17.86% | $8.03 Billion | $44.98 Billion | +2.30pp |
| 2016-12-31 | 15.56% | $6.04 Billion | $38.81 Billion | +13.35pp |
| 2015-12-31 | 2.21% | $785.40 Million | $35.57 Billion | -0.42pp |
| 2014-12-31 | 2.63% | $955.40 Million | $36.31 Billion | -1.81pp |
| 2013-12-31 | 4.45% | $1.57 Billion | $35.25 Billion | -0.40pp |
| 2012-12-31 | 4.84% | $1.67 Billion | $34.40 Billion | +1.95pp |
| 2011-12-31 | 2.90% | $974.60 Million | $33.66 Billion | +0.53pp |
| 2010-12-31 | 2.37% | $733.80 Million | $31.00 Billion | +2.24pp |
| 2009-12-31 | 0.13% | $34.70 Million | $27.46 Billion | -1.34pp |
| 2008-12-31 | 1.47% | $429.40 Million | $29.21 Billion | -4.54pp |
| 2007-12-31 | 6.01% | $1.61 Billion | $26.79 Billion | +2.45pp |
| 2006-12-31 | 3.56% | $781.70 Million | $21.96 Billion | -4.70pp |
| 2005-12-31 | 8.26% | $2.03 Billion | $24.58 Billion | -0.18pp |
| 2004-12-31 | 8.44% | $2.10 Billion | $24.87 Billion | +4.03pp |
| 2003-12-31 | 4.41% | $957.00 Million | $21.68 Billion | -4.56pp |
| 2002-12-31 | 8.97% | $1.71 Billion | $19.04 Billion | +2.71pp |
| 2001-12-31 | 6.26% | $1.03 Billion | $16.43 Billion | +2.83pp |
| 2000-12-31 | 3.43% | $503.30 Million | $14.69 Billion | +2.37pp |
| 1999-12-31 | 1.06% | $135.60 Million | $12.83 Billion | -- |